<< Chemo instead of radiotherapy cuts long-term side effects for children with brain tumours | Nanotechnology to test food quality >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Court dismisses Gen-Probe court action against Digene

Published on July 23, 2007 at 11:33 AM · No Comments

Digene Corp. has announced that a California state court has dismissed a complaint filed against the company by Gen-Probe, Inc., without option to amend. Gen-Probe's complaint asked the court to declare that an agreement between Gen-Probe and F. Hoffman-LaRoche Ltd. and Roche Molecular Systems, Inc. for the supply and purchase of certain HPV-related materials was permissible under the terms of a pre-existing cross-license patent agreement between Roche and Digene.

Ruling in favor of Digene's request for dismissal, the Superior Court for the County of San Diego stated that there is "no actual controversy between Digene and Gen-Probe." By prohibiting any further amendment of the complaint, the court has terminated the litigation brought by Gen-Probe against Digene, with no option to re-file.

Daryl Faulkner, president and chief executive officer of Digene, commented: "We are very pleased with this result, and with the termination of this litigation. The court's dismissal of this petition with no option to amend and re-file clearly recognizes the merits of our position. Digene is the worldwide leader of products for the detection of human papillomavirus, the cause of cervical cancer, and this is due in large part to our strong portfolio of intellectual property, as well as to our innovation in science and excellence in marketing execution."

http://www.digene.com/

Posted in: Medical Patent News

Tags: , , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading